Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resistance Mutations”

239 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 239 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04127110
What this trial is testing

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 68
Not applicableWithdrawnNCT04219111
What this trial is testing

Gene Expression Profiles in CML Non-responders

Who this might be right for
Gene Expression Profiles in CML Non-responders
Sheffield Children's NHS Foundation Trust
Testing effectiveness (Phase 2)Study completedNCT00109590
What this trial is testing

Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 175
Not applicableStudy completedNCT06285110
What this trial is testing

HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen

Who this might be right for
Hiv
University of Bern 1,103
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Testing effectiveness (Phase 2)UnknownNCT00299897
What this trial is testing

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

Who this might be right for
HIV InfectionsHuman Immunodeficiency Virus
Samaritan Pharmaceuticals, Inc 60
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Testing effectiveness (Phase 2)Study completedNCT03117933
What this trial is testing

Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
University of Oxford 139
Testing effectiveness (Phase 2)Looking for participantsNCT05470504
What this trial is testing

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

Who this might be right for
Insulin Receptor MutationPartial Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 25
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Post-approval studies (Phase 4)Not Yet RecruitingNCT06893354
What this trial is testing

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 20
Not applicableActive Not RecruitingNCT06733337
What this trial is testing

Learn About the Safety of TALZENNA in People With Prostate Cancer.

Who this might be right for
Prostate Cancer
Pfizer 1
Large-scale testing (Phase 3)UnknownNCT04055038
What this trial is testing

Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)

Who this might be right for
Ovarian CancerOvarian NeoplasmsSerous Adenocarcinoma+3 more
Blokhin's Russian Cancer Research Center 164
Not applicableUnknownNCT06081270
What this trial is testing

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer

Who this might be right for
Lung Cancer
University of Milano Bicocca 20
Post-approval studies (Phase 4)Study completedNCT03683524
What this trial is testing

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

Who this might be right for
HIV-1 Infection
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia 96
Testing effectiveness (Phase 2)Looking for participantsNCT07405801
What this trial is testing

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Testing effectiveness (Phase 2)UnknownNCT05327621
What this trial is testing

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University 50
Testing effectiveness (Phase 2)Study completedNCT00997334
What this trial is testing

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer
David M. Jackman, MD 60
Testing effectiveness (Phase 2)Looking for participantsNCT06514534
What this trial is testing

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Who this might be right for
Chronic Myeloid Leukemia (CML)
Novartis Pharmaceuticals 20
Next Page